Iterum Therapeutics Announced That The U.S. FDA Has Acknowledged Receipt Of The Resubmission Of The NDA For Sulopenem Etzadroxil/Probenecid For The Treatment Of UTIs
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics has received FDA acceptance for its resubmission of a New Drug Application (NDA) for oral sulopenem, aimed at treating uncomplicated urinary tract infections.
May 31, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iterum Therapeutics has received FDA acceptance for its resubmission of a New Drug Application (NDA) for oral sulopenem, aimed at treating uncomplicated urinary tract infections.
FDA acceptance of an NDA resubmission is a positive regulatory milestone, indicating progress towards potential approval. This can boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100